EPISODE · Nov 14, 2023 · 10 MIN
RNA test identifies large B-cell lymphoma subtypes: Lisa Rimsza, M.D.
from Answers from the Lab · host Mayo Clinic Laboratories
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately define subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy for these cancers.Speaker 2: (00:32) Could you provide a brief background about yourself? Speaker 2: (01:12) Would you give us an overview of the PM3CX test? Speaker 2: (03:02) Which patients should have this testing? Speaker 2: (05:14) Is this test qualitative and RNA? Speaker 2: (06:35) After determining if it's primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma, does the test identify the cell of origin? Speaker 2: (08:09) For patients diagnosed with diffuse large B-cell lymphoma, what are the treatment recommendations? Speaker 2: (09:04)Are there any other insights about this test that you'd like to share?
What this episode covers
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately define subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy for these cancers.Speaker 2: (00:32) Could you provide a brief background about yourself? Speaker 2: (01:12) Would you give us an overview of the PM3CX test? Speaker 2: (03:02) Which patients should have this testing? Speaker 2: (05:14) Is this test qualitative and RNA? Speaker 2: (06:35) After determining if it's primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma, does the test identify the cell of origin? Speaker 2: (08:09) For patients diagnosed with diffuse large B-cell lymphoma, what are the treatment recommendations? Speaker 2: (09:04)Are there any other insights about this test that you'd like to share?
NOW PLAYING
RNA test identifies large B-cell lymphoma subtypes: Lisa Rimsza, M.D.
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m